Cinacalcet 30mg, 60mg, 90mg, tabs.
Study is the largest to explore this potential safety issue to date.
Overall control of hyperparathyroidism and hyperphosphatemia appeared to be associated with a reduction in left ventricular mass, however.
A recent findings, if validated, may partly explain inter-individual differences in the response to cinacalcet treatment for secondary hyperparathyroidism.
Trends suggest that clinical practice could be driven heavily by providers’ preferences and beliefs, resulting in substantial practice variation.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
The FDA has stopped all pediatric clinical trials of Sensipar (cinacalcet HCl; Amgen) after a recent death of a 14-year-old patient in a trial.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of August. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
A study appearing in the Journal of the American Society of Nephrology concluded vitamin D supplements did not help treat anemia in patients on hemodialysis.
Metastatic calcification of the left
breast in a patient with renal failure